Correlation between Metabolite of Prostaglandin E2 and the incidence of colorectal adenomas

Jia Jiang, Anjie Li, Xiaolian Lai, Hanqun Zhang, Chonghong Wang, Huimin Wang, Libo Li, Yuncong Liu, Lu Xie, Can Yang, Cui Zhang, Shuoyan Lu, Yong LiFrontiers in Oncology 2023 · DOI

Abstract

Colorectal cancer is a common malignancy, and the incidence and mortality rates continue to rise. An important factor in the emergence of inflammation-induced colorectal carcinogenesis is elevated cyclooxygenase-2. Prostaglandin E2 (PGE2) over-production is frequently equated with cyclooxygenase-2 gene over-expression. PGE2 can be assessed by measuring the level of prostaglandin's main metabolite, PGE-M, in urine. Colorectal adenoma is a precancerous lesion that can lead to colorectal cancer. We conducted research to evaluate the association between urinary levels of the PGE-M and the risk of colorectal adenomas. In a western Chinese population, we identified 152 cases of adenoma and 152 controls patients without polyps. Adenoma cases were categorized into control, low-risk and high-risk groups. There was no significant change in PGE-M levels, between the control group and the low-risk adenoma group. In the high-risk group, the PGE-M levels were 23% higher than the control group. When compared to people with the lowest urine PGE-M levels (first quartile), people with greater urinary PGE-M levels had a higher chance of developing high-risk colorectal adenomas, with an adjusted odds ratio (95% CI) of 1.65 (0.76-3.57) in the fourth quartile group, (p= 0.013). We conclude urinary PGE-M is associated with the risk of developing high-risk adenomas. Urinary PGE-M level may be used as a non-invasive indicator for estimating cancer risk.

Introduction

Colorectal cancer (CRC) remains a significant global health challenge, with rising incidence rates particularly noted in China. The progression from benign polyps (adenomas) to malignant tumors—the "adenoma-carcinoma sequence"—is a well-documented pathway for CRC development. Early identification of high-risk adenomas, characterized by size (≥1 cm), villous features, or high-grade dysplasia, is paramount for effective prevention.

Inflammation is a known driver of this progression, specifically involving the enzyme cyclooxygenase-2 (COX-2) and its product, Prostaglandin E2 (PGE2). However, PGE2 is highly unstable, making it difficult to measure in clinical settings. This study investigates whether PGE-M, the stable urinary metabolite of PGE2, can serve as a non-invasive biomarker for identifying high-risk colorectal adenomas in a Western Chinese population.

Methods

This case-control study involved 304 participants (152 adenoma cases and 152 healthy controls) from hospitals in Guizhou Province, China. Participants were categorized based on clinical findings:

  • Controls: Patients without polyps.
  • Low-risk Adenoma: Single tubular adenomas <1 cm.
  • High-risk Adenoma: Adenomas ≥1 cm, with villous features, high-grade dysplasia, or multiple adenomas.

Urinary PGE-M levels were quantified using Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS) and normalized against urinary creatinine to account for concentration variance. Statistical analysis utilized logistic regression to calculate Odds Ratios (ORs), adjusting for variables such as age, sex, BMI, and dietary factors like calcium intake.

Baseline characteristics of the study population across control and case groups.

Results

The study revealed a distinct correlation between PGE-M levels and the severity of adenomas. While PGE-M levels in low-risk adenoma patients did not differ significantly from controls, the high-risk group exhibited levels 23% higher than the control group.

Comparison of urinary PGE-M levels (median and geometric mean) between controls and adenoma risk groups.

Key findings include:

  • Risk Association: Participants in the highest quartile of urinary PGE-M levels had a significantly increased risk of high-risk adenomas compared to the lowest quartile.
  • Statistical Significance: The adjusted Odds Ratio (OR) for the fourth quartile was 1.65 (95% CI: 0.76–3.57), with a significant trend across quartiles (p = 0.013).
  • Quantitative Data: The geometric mean of PGE-M in the high-risk group was 12.06 ng/mg creatinine, compared to 9.76 ng/mg in the control group.

Discussion

The findings suggest that PGE-M is a specific marker for disease progression rather than the mere presence of any polyp. By reflecting systemic PGE2 production, PGE-M acts as a proxy for the inflammatory environment conducive to tumor growth. Interestingly, the association appeared stronger in women and individuals with higher BMI (≥25 kg/m²). Furthermore, the regional context of Western China, where calcium deficiency is common, may influence these inflammatory markers, as calcium is hypothesized to modulate the inflammatory response.

Limitations and Future Directions

The study's sample size was constrained by the COVID-19 pandemic, potentially limiting the power of subgroup analyses. Additionally, the cross-sectional nature of the study means longitudinal data is required to track PGE-M changes during the actual transition from adenoma to carcinoma. Future research should focus on the genetic drivers of PGE2 overproduction and their interaction with environmental and dietary factors.

Conclusion

Urinary PGE-M is significantly associated with the risk of high-risk colorectal adenomas. As a stable and non-invasive biomarker, it holds potential for clinical use in estimating cancer risk and identifying individuals who require more intensive screening or intervention.

Summary updated

Abstract

Colorectal cancer is a common malignancy, and the incidence and mortality rates continue to rise. An important factor in the emergence of inflammation-induced colorectal carcinogenesis is elevated cyclooxygenase-2. Prostaglandin E2 (PGE<sub>2</sub>) over-production is frequently equated with cyclooxygenase-2 gene over-expression. PGE<sub>2</sub> can be assessed by measuring the level of prostaglandin's main metabolite, PGE-M, in urine. Colorectal adenoma is a precancerous lesion that can lead to colorectal cancer. We conducted research to evaluate the association between urinary levels of the PGE-M and the risk of colorectal adenomas. In a western Chinese population, we identified 152 cases of adenoma and 152 controls patients without polyps. Adenoma cases were categorized into control, low-risk and high-risk groups. There was no significant change in PGE-M levels, between the control group and the low-risk adenoma group. In the high-risk group, the PGE-M levels were 23% higher than the control group. When compared to people with the lowest urine PGE-M levels (first quartile), people with greater urinary PGE-M levels had a higher chance of developing high-risk colorectal adenomas, with an adjusted odds ratio (95% CI) of 1.65 (0.76-3.57) in the fourth quartile group, (p= 0.013). We conclude urinary PGE-M is associated with the risk of developing high-risk adenomas. Urinary PGE-M level may be used as a non-invasive indicator for estimating cancer risk.
BibTeX
@inproceedings{jiang2023correlation,
  author = {Jia Jiang and Anjie Li and Xiaolian Lai and Hanqun Zhang and Chonghong Wang and Huimin Wang and Libo Li and Yuncong Liu and Lu Xie and Can Yang and Cui Zhang and Shuoyan Lu and Yong Li},
  title = {{Correlation between Metabolite of Prostaglandin E2 and the incidence of colorectal adenomas}},
  booktitle = {Frontiers in Oncology},
  year = {2023},
  doi = {10.3389/fonc.2023.1068469},
}
Figure